Cytek Biosciences Inc. Releases Investor Presentation Highlighting Leading Cell Analysis Tools and 2025 Outlook

Reuters

2025/09/10

Cytek Biosciences Inc. Releases Investor Presentation Highlighting Leading Cell Analysis Tools and 2025 Outlook

Cytek Biosciences Inc. presented its September 2025 Investor Presentation, highlighting its achievements and financial performance. The company reported a strong financial profile with a total trailing twelve months $(TTM)$ revenue of $196.0 million, which includes a 16% year-over-year increase in recurring revenue. Cytek detailed its product lineup, including the launch of the Evo Analyzer in 2025 and the ESP Detection Option in 2024. The company has placed 3,295 units globally, serving approximately 2,000 customers across over 70 countries. Moreover, Cytek has been recognized with the 2024 Biotech Breakthrough Award as the Overall Biotech Company of the Year. The presentation also outlined the company's revenue guidance for 2025, projecting between $196 million and $205 million. Cytek maintains a cash and marketable securities position of $262 million. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cytek Biosciences Inc. published the original content used to generate this news brief on September 09, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2566418726"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2566418726\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2566418726?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-10 06:59","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2566418726","market":"us","top_or_hot":-1,"title":"Cytek Biosciences Inc. Releases Investor Presentation Highlighting Leading Cell Analysis Tools and 2025 Outlook","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Cytek Biosciences Inc. Releases Investor Presentation Highlighting Leading Cell Analysis Tools and 2025 Outlook\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Cytek Biosciences Inc. presented its September 2025 Investor Presentation, highlighting its achievements and financial performance. The company reported a strong financial profile with a total trailing twelve months <a href=\"https://laohu8.com/S/TTM\">$(TTM)$</a> revenue of $196.0 million, which includes a 16% year-over-year increase in recurring revenue. Cytek detailed its product lineup, including the launch of the Evo Analyzer in 2025 and the ESP Detection Option in 2024. The company has placed 3,295 units globally, serving approximately 2,000 customers across over 70 countries. Moreover, Cytek has been recognized with the 2024 Biotech Breakthrough Award as the Overall Biotech Company of the Year. The presentation also outlined the company's revenue guidance for 2025, projecting between $196 million and $205 million. Cytek maintains a cash and marketable securities position of $262 million. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cytek Biosciences Inc. published the original content used to generate this news brief on September 09, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cytek Biosciences Inc. Releases Investor Presentation Highlighting Leading Cell Analysis Tools and 2025 Outlook</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCytek Biosciences Inc. Releases Investor Presentation Highlighting Leading Cell Analysis Tools and 2025 Outlook\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-09-10 06:59</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Cytek Biosciences Inc. Releases Investor Presentation Highlighting Leading Cell Analysis Tools and 2025 Outlook\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Cytek Biosciences Inc. presented its September 2025 Investor Presentation, highlighting its achievements and financial performance. The company reported a strong financial profile with a total trailing twelve months <a href=\"https://laohu8.com/S/TTM\">$(TTM)$</a> revenue of $196.0 million, which includes a 16% year-over-year increase in recurring revenue. Cytek detailed its product lineup, including the launch of the Evo Analyzer in 2025 and the ESP Detection Option in 2024. The company has placed 3,295 units globally, serving approximately 2,000 customers across over 70 countries. Moreover, Cytek has been recognized with the 2024 Biotech Breakthrough Award as the Overall Biotech Company of the Year. The presentation also outlined the company's revenue guidance for 2025, projecting between $196 million and $205 million. Cytek maintains a cash and marketable securities position of $262 million. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cytek Biosciences Inc. published the original content used to generate this news brief on September 09, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CTKB","symbol_name":"Cytek BioSciences","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250909:nNDL8Mttsp:1","article_id":"2566418726","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2566418726","pubTimestamp":1757458787,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Cytek Biosciences Inc. presented its September 2025 Investor Presentation, highlighting its achievements and financial performance. The company reported a strong financial profile with a total trailing twelve months  revenue of $196.0 million, which includes a 16% year-over-year increase in recurring revenue. Cytek detailed its product lineup, including the launch of the Evo Analyzer in 2025 and the ESP Detection Option in 2024. The company has placed 3,295 units globally, serving approximately 2,000 customers across over 70 countries. Moreover, Cytek has been recognized with the 2024 Biotech Breakthrough Award as the Overall Biotech Company of the Year. The presentation also outlined the company's revenue guidance for 2025, projecting between $196 million and $205 million. Cytek maintains a cash and marketable securities position of $262 million. You can access the full presentation through the link below.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CTKB":"Cytek BioSciences","BK4121":"生命科学工具和服务","BK4539":"次新股"},"translate_title":"Cytek Biosciences Inc.发布投资者演讲，重点介绍领先的细胞分析工具和2025年展望","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CTKB":0.9},"content_text":"Cytek Biosciences Inc. Releases Investor Presentation Highlighting Leading Cell Analysis Tools and 2025 Outlook\n    \n\n        Cytek Biosciences Inc. presented its September 2025 Investor Presentation, highlighting its achievements and financial performance. The company reported a strong financial profile with a total trailing twelve months $(TTM)$ revenue of $196.0 million, which includes a 16% year-over-year increase in recurring revenue. Cytek detailed its product lineup, including the launch of the Evo Analyzer in 2025 and the ESP Detection Option in 2024. The company has placed 3,295 units globally, serving approximately 2,000 customers across over 70 countries. Moreover, Cytek has been recognized with the 2024 Biotech Breakthrough Award as the Overall Biotech Company of the Year. The presentation also outlined the company's revenue guidance for 2025, projecting between $196 million and $205 million. Cytek maintains a cash and marketable securities position of $262 million. You can access the full presentation through the link below.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cytek Biosciences Inc. published the original content used to generate this news brief on September 09, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}